Immunovant is a clinical-stage company dedicated to enabling normal lives for people with autoimmune diseases. A key priority is Graves’ disease and related conditions, such as thyroid eye disease. From engaging with people living with these conditions and the doctors who care for them, we know that symptoms can have a significant impact on an individual’s emotional well-being and daily life. We are focused on developing a targeted investigational therapy to address the underlying cause of these related diseases. Through our ongoing clinical research, we hope to drive further progress and reframe expectations in care.

How to reach us
Send an email: patientadvocacy@immunovant.com
Visit our website: Immunovant.com

Immunovant’s Clinical Development Programs for People Living with Graves’ Disease and TED

FORWARD / FORWARD2 for adults with Graves’ disease
https://graves.clinicalenrollment.com
In this study, researchers are testing whether an investigational drug called IMVT-1402 will help people with Graves’ disease. “Investigational” means that the drug has not been approved for use by any regulatory authority in patients, except in a clinical study. The study drug is designed to work differently from antithyroid drugs, by targeting the underlying cause of Graves’ disease. Since Graves’ disease (GD) is an autoimmune disease caused by antibodies, a possible disease-modifying approach researchers are examining is to target a receptor that would potentially lead to antibody reduction.

GO1 / GO2 for adults with thyroid eye disease
The GO1 and GO2 Phase 3 clinical trials for adults with thyroid eye disease are no longer recruiting participants. Immunovant anticipates sharing initial results from both of these clinical trials in the first half of 2026.

Immunovant’s Commitment to Advancing Care in Autoimmune Disease

What is your company’s focus when it comes to helping people living with TED and when did you start working in the TED space?
Immunovant’s focus is on developing a targeted investigational therapy that is designed to block the harmful autoantibodies that cause Graves’ disease and may later lead to TED, also known as Graves’ eye disease, Graves’ ophthalmopathy or Graves’ orbitopathy.

We have been advancing clinical research in Graves’ ophthalmopathy, or TED, since 2018, and we anticipate sharing initial results from both of our Phase 3 clinical trials in the first half of 2026. We also are conducting clinical studies in Graves’ disease, where treatment options have remained unchanged for more than 70 years. Importantly, none of the existing Graves’ disease treatments target the underlying autoimmune disease driver. We are exploring an approach that targets the harmful autoantibodies that cause Graves’ disease symptoms to see if we can potentially improve outcomes.

What is the therapeutic approach for your investigational treatment?
In autoimmune disease, the immune system attacks the body by mistake. In some cases, harmful autoantibodies play a key role. Graves’ disease is a common autoimmune condition in which autoantibodies attack the thyroid, causing the overproduction of thyroid hormones, known as hyperthyroidism. In TED, these autoantibodies attack the tissue around the eye, causing inflammation.

We are focused on developing a targeted investigational therapy to help reduce the amount of harmful autoantibodies. Our technology is designed to work with the body’s own antibody recycling process. The neonatal Fc receptor (FcRn) helps maintain antibody levels in your body. By blocking the FcRn receptor, we aim to reduce the amount of harmful autoantibodies circulating in the body that cause symptoms.

What symptoms are you measuring the impact of the investigational treatment on in your clinical trials?
Our clinical studies are designed to look at the safety of our investigational therapies and how well they work (efficacy). Through listening to the community, we’re focused on the symptoms that matter. In our TED trials, we’re looking at the impact on swollen, bulging eyes (proptosis). In our Graves’ disease trials, we’re looking at achieving normal thyroid hormone levels so that participants are no longer hyperthyroid and no longer need medication.

Where can people go to learn more about your clinical trials, and how can people find out if they are eligible to participate?
To learn more about our ongoing clinical research in Graves’ disease, visit: https://graves.clinicalenrollment.com

How do patients’ voices and experiences influence your research and product development?
At Immunovant, the lived experience of people with autoimmune disease is our purpose and north star. The needs of people living with autoimmune conditions guide our science, our priorities and our standards. From convening patient councils to ongoing dialogue with advocates, we are listening, learning and applying community insights to our work. We act with urgency and aim to push boundaries because we know that every moment matters.